- 10:42 PM Are stricter rules for MF advertisements on anvil?
- 10:31 PM NSE to launch new MF service system on Nov 30
- 10:16 PM India indispensable to America's future: Barack Ob...
- 10:00 PM Subir Gokarn’s agenda:Stimulus exit not to hit eco...
- 09:16 PM Worst over for India auto companies: Anand Mahindr...
- 08:52 PM Edelweiss, Tokio Marine ink insurance JV
- 08:42 PM Aviation biz to contribute 5% to rev in 3-5 years:...
- 08:24 PM Inflow of money will not help curb inflation: Bima...
- 07:17 PM MphasiS Q4 cons net profit up 33.9% at Rs 245 cr
- 06:59 PM Immediate supports for rupee at 46.20/46.10: Commt...



Cognizant (NASDAQ: CTSH), a leading provider of global IT and business process outsourcing services, today announced an agreement with AstraZeneca to support the company’s drive for greater efficiencies in Clinical Data Management. AstraZeneca is one of the world’s largest pharmaceutical companies, widely recognized for its life-changing medicines. The contract is for a period of five years with anticipated revenues of approximately $95 million.
Under this agreement, Cognizant will provide a broad spectrum of centralized data management services for AstraZeneca’s global clinical development programs, including data management planning, clinical study set-up for electronic data capture, medical coding, adverse event reconciliation, clinical data management, and training for the clinical sites and investigators. The intention to centralize these services was announced by AstraZeneca last year as part of its effort to drive R&D efficiencies.
“We are strongly committed to leveraging our deep understanding of the pharmaceutical industry, our leadership in clinical management solutions and our global footprint to help AstraZeneca’s drive to innovate and continue to make a real difference in the way it delivers healthcare,” said Francisco D’Souza, President and CEO, Cognizant. “We will help AstraZeneca centralize and streamline its clinical data management operations through improved process standardization, consistency of delivery, economies of scale and cost savings that AstraZeneca can reinvest to support the fast, innovative and efficient development of their R&D programs.”
“Our existing, long-standing relationship with Cognizant supports our view that they are the best partner to deliver clinical data management services for us,” said Anders Ekblom, Vice President of Clinical Development, AstraZeneca. “Delivering efficiencies through reshaping our business is one of our key strategic priorities.”
In 2004 AstraZeneca engaged Cognizant for other business services across North America, Europe and Asia Pacific. These services encompass a broad range of well-integrated business process and technology solutions that span discovery, clinical, manufacturing and commercial operations.
Sourced From: Cognizant
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Mitesh Thacker's top 5 picks for trade today

- Ganeshaspeaks: Market prediction for Nov 24
- Will ITC dream run continue beyond FY10?

- Den Networks slips 22% after listing at Rs 195
- Trading in MF units to start in 15 days: SEBI

- Why LyondellBasell is a goldmine for RIL

- Experts see mkts at new highs, advise sectors

- Corrections in '10 to be more aggressive, violent: JPMorgan

- Mahindra may increase car prices due to rising input costs
Source: Business Line
- Renault to continue with M&M for Logan, says Ghosn
Source: Business Line
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line










